Skip to content
Triangle logo TriangleGet started
← Full study record

NCT03951220 · ADVERSE EVENTS

Adverse events

The Development and Pilot Testing of a New MR Imaging Protocol to Quantify Myeloma Disease Burden and Bone Loss · Source last updated 2025-08-19

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Adverse events occurred during the study; they are not necessarily caused by treatment. Serious events are not interchangeable with severe/grade 3–4 events. These safety populations may differ from efficacy populations.

Collection time frame
The intention of this study was to assess the value of disease assessment of candidate biomarkers (using DW-MRI and analysis of peripheral blood). Therefore, all-Cause Mortality, Serious, and Other [Not Including Serious] Adverse Events were not monitored/assessed.
Other-event reporting threshold
0%

The intention of this study was to assess the value of disease assessment of candidate biomarkers (using DW-MRI and analysis of peripheral blood). Therefore, all-Cause Mortality, Serious, and Other \[Not Including Serious\] Adverse Events were not monitored/assessed.

Participants affected / participants at risk, as reported
Safety groupSerious eventsOther eventsDeaths
Group 1- Myeloma

Participants recruited with myeloma

0 / 00 / 00 / 0
Group 2- MGUS

Participants recruited with MGUS

0 / 00 / 00 / 0
Group 3- Healthy Volunteers

Participants recruited as healthy volunteers

0 / 00 / 00 / 0

Group identifiers: EG000: Group 1- Myeloma · EG001: Group 2- MGUS · EG002: Group 3- Healthy Volunteers

Serious adverse events

Event terms and counts are source-reported; expand to read more. A reporting threshold may omit less frequent events.

    Other reported adverse events

    Event terms and counts are source-reported; expand to read more. A reporting threshold may omit less frequent events.

      Complete source fields
      description
      The intention of this study was to assess the value of disease assessment of candidate biomarkers (using DW-MRI and analysis of peripheral blood). Therefore, all-Cause Mortality, Serious, and Other \[Not Including Serious\] Adverse Events were not monitored/assessed.
      event Groups
      1. deaths Num Affected
        0
        deaths Num At Risk
        0
        description
        Participants recruited with myeloma
        id
        EG000
        other Num Affected
        0
        other Num At Risk
        0
        serious Num Affected
        0
        serious Num At Risk
        0
        title
        Group 1- Myeloma
      2. deaths Num Affected
        0
        deaths Num At Risk
        0
        description
        Participants recruited with MGUS
        id
        EG001
        other Num Affected
        0
        other Num At Risk
        0
        serious Num Affected
        0
        serious Num At Risk
        0
        title
        Group 2- MGUS
      3. deaths Num Affected
        0
        deaths Num At Risk
        0
        description
        Participants recruited as healthy volunteers
        id
        EG002
        other Num Affected
        0
        other Num At Risk
        0
        serious Num Affected
        0
        serious Num At Risk
        0
        title
        Group 3- Healthy Volunteers
      frequency Threshold
      0
      time Frame
      The intention of this study was to assess the value of disease assessment of candidate biomarkers (using DW-MRI and analysis of peripheral blood). Therefore, all-Cause Mortality, Serious, and Other [Not Including Serious] Adverse Events were not monitored/assessed.

      Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

      Preserved source evidence · Not medical advice